Mankind Pharma Limited

Mankind Pharma Limited (MANKIND) is a mid-cap Healthcare company valued at ₹93,968 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Mankind Pharma Limited last traded at ₹2,275.5, down 3.07% on the day.

Recent developments

On 2026-10-15, the company announced an acquisition of a 70% stake in Belgium’s ACTx for €48 million, which is expected to enhance its global pharmaceutical research capabilities. On 2026-10-12, the company held an earnings conference call for its Q2 H1 FY27 results. On 2026-09-29, the company's stock rose along with other pharma stocks due to US tariff exemptions on certain specialty drugs.

Financial performance

The company's annual revenue rose 17.0% to ₹14,278 crore, while annual net profit fell 3.6% to ₹1,938 crore. The latest quarter saw revenue increase 12.9% to ₹4,031 crore and net profit rise 29.0% to ₹574 crore, showing stronger performance in the most recent period compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 49.1 times earnings, a premium to the Healthcare median of 32.0, 5.69 times book value. It yields 0.0%.

Things to watch

The company's net profit margin narrowed 2.9 percentage points to 13.6% from 16.5% in the prior year. The stock is 13.9% below its 52-week high, and foreign institutional holding decreased by 0.08 percentage points in the quarter.

Where it stands

The company's business has shown strong revenue growth over the past five years, with a 18.1% CAGR, but net profit growth has slowed, with a 8.4% CAGR over five years. The latest quarter marked a significant improvement in net profit, rising 29.0% compared to the same quarter a year earlier. The stock is currently 13.9% below its 52-week high.

Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.